What is Diligent Pharma?
Diligent Pharma operates as a private vendor management qualification organization, providing a centralized technology platform designed to streamline the complex process of vendor qualification within clinical trial execution. The company's solution addresses critical needs for efficiency and compliance in a highly regulated industry.
How much funding has Diligent Pharma raised?
Diligent Pharma has raised a total of $8.3M across 1 funding round:
Series A
$8.3M
Series A (2023): $8.3M with participation from Point Judith Capital, GenHenn Capital, and FCA Venture Partners
Key Investors in Diligent Pharma
Point Judith Capital
Point Judith Capital is an early-stage venture capital firm focused on investing in, supporting, and building relationships with entrepreneurs. They are located in Boston, Massachusetts and were founded in 2001.
GenHenn Capital
Undisclosed investor participating in the funding round.
FCA Venture Partners
FCA Venture Partners is an investment firm focused on transforming healthcare by backing companies that enhance patient care, empower providers, and reduce costs. With over 50 investments and $285 million in capital raised, they have developed expertise in four key sectors: providers, payers, pharma, and innovative care delivery.
What's next for Diligent Pharma?
The recent major strategic investment signals a phase of accelerated growth and market expansion for Diligent Pharma. This financing is expected to fuel further development of its platform, enhance its market reach, and solidify its position as a leader in clinical trial vendor qualification. The company is poised to leverage this capital to deepen its impact on operational efficiency for its clients.
See full Diligent Pharma company page
